Cleveland Clinic-Led Trial Finds That Experimental ‘Gene Silencing’ Therapy Reduces Lipoprotein(a), an Important Risk Factor of Heart Disease, By Up To 98%

Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental “gene silencing” therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.

Findings from the “APOLLO Trial: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial” were presented today during a late-breaking science session at American College of Cardiology’s 71st Annual Scientific Session and simultaneously published online in the Journal of the American Medical Association.

Mount Sinai Cardiovascular Doctors to Receive Honors During American College of Cardiology 70th Annual Scientific Session

William Whang, MD, Associate Professor of Medicine (Cardiology), and Gilbert Tang, MD, MSc, MBA, Associate Professor of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai, are receiving the 2021 Simon Dack Awards for their exceptional contributions to the Journal of the American College of Cardiology (JACC).